Results 241 to 250 of about 2,786,283 (323)
Testing the effects of nutrition-related claims on perceptions of and preferences for alcohol products among Australian consumers. [PDF]
Yusoff A +5 more
europepmc +1 more source
Overview: The Role of Consumer Research Evidence in Recent National Advertising Regulation [PDF]
Andrews, J. Craig
core +1 more source
Abstract Background Body composition and energy metabolism assessments are central to nutrition care but remain underused. This study evaluated dietitians’ access, use, education, and beliefs toward these assessments, and the impact of an educational session.
Camila E. Orsso +17 more
wiley +1 more source
The Prevalence and Compliance of Health Claims on Food Supplements with Regulation (EC) No. 1924/2006 Sold In-Store and Online Within the Republic of Ireland. [PDF]
Barrow N, Hoey L, Verhagen H.
europepmc +1 more source
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu +13 more
wiley +1 more source
Government Efforts to Aid Consumer Well-being: Understanding Federal Health Warnings and Disclosures [PDF]
Andrews, J. Craig +2 more
core +1 more source
ABSTRACT Objective Antiobesity medications (AOMs) are indicated for long‐term use; however, evidence of their real‐world long‐term efficacy is limited. This study describes clinical outcomes from 18‐ and 24‐month use of AOMs in a telemedicine weight management clinic.
Kathleen R. Ruddiman +7 more
wiley +1 more source
NutriWomen, Novel Evidence-Based Web Platform to Support Women's Health, Nutrition Decisions and Address Nutrition Misinformation on Social Media: Protocol for a Digital Tool Development. [PDF]
Bosch Pujadas M +5 more
europepmc +1 more source
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone +3 more
wiley +1 more source
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez +10 more
wiley +1 more source

